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Summary
Human xenobiotic-metabolizing cytochrome P450 (P450) enzymes can each bind and
monooxygenate a diverse set of substrates, including drugs, often producing a variety of
metabolites. Additionally a single ligand can interact with multiple cytochrome P450 enzymes, but
often the protein structural similarities and differences that mediate such overlapping selectivity
are not well understood. Even though the P450 superfamily has a highly canonical global protein
fold, there are large variations in the active site size, topology, and conformational flexibility. We
have determined how a related set of three human cytochrome P450 enzymes bind and interact
with a common inhibitor, the muscarinic receptor agonist drug pilocarpine. Pilocarpine binds and
inhibits the hepatic CYP2A6 and respiratory CYP2A13 enzymes much more efficiently than the
hepatic CYP2E1 enzyme. To elucidate key amino acids involved in pilocarpine binding, crystal
structures of CYP2A6 (2.4 Å), CYP2A13 (3.0 Å), CYP2E1 (2.35 Å), and a CYP2A6 mutant
enzyme, CYP2A6 I208S/I300F/G301A/S369G (2.1 Å), have been determined with pilocarpine in
the active site. In all four structures, pilocarpine coordinates to the heme iron, but comparisons
reveal how individual amino acids lining the active sites of these three distinct human enzymes
interact differently with the inhibitor pilocarpine.
Hyperlinking to databases—The atomic coordinates and structure factors have been
deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers
University, New Brunswick, NJ (http://www.rcsb.org/) with the following codes: CYP2A6 with
pilocarpine (3T3R), CYP2A6 I208S/I300F/G301A/S369G with pilocarpine (3T3Q), CYP2A13
with pilocarpine (3T3S), and CYP2E1 with pilocarpine (3T3Z).
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The cytochrome P450 superfamily contains enzymes that catalyze oxidative metabolism of
the myriad of lipophilic drugs and xenobiotics to which humans are exposed. Each different
cytochrome P450 enzyme can bind, metabolize, and be inhibited by a distinctive set of
chemically and structurally diverse compounds. However, a single compound can often
interact with multiple P450 enzymes. Understanding the structural basis for this overlapping
ligand selectivity is important in order to rationalize and predict the participation of various
human cytochrome P450 enzymes in drug and xenobiotic metabolism, as well as their
respective susceptibilities to inhibitors.
In humans, the CYP2A and CYP2E subfamilies represent an excellent system for such
structure/function investigations. In humans, the functional CYP2A enzymes consist of two
94% identical enzymes: CYP2A6, which is largely hepatic [1], and CYP2A13, which is
primarily located in the respiratory tract [2, 3]. Humans also have a single CYP2E1 enzyme,
which is primarily hepatic [1] and has less than 40% amino acid identity compared to the
CYP2A enzymes. Nonetheless, CYP2E1 oxidizes and is inhibited by many of the same
compounds as CYP2A enzymes. For example, p-nitrophenol and chlorzoxazone have
traditionally been used as substrates to indicate the presence of active CYP2E1 protein,
especially in microsomes where mixtures of P450 enzymes are present, but CYP2A13 has a
higher catalytic efficiency than CYP2E1 for both substrates [4]. In comparison, CYP2A6
has a lower catalytic efficiency for chlorzoxazone 6-hydroxylation and equivalent catalytic
efficiency for p-nitrophenol 2-hydroxylation compared to CYP2E1 [4]. Styrene and toluene
are also metabolized by CYP2E1, CYP2A13, and CYP2A6 [4].
Although there are various structures available of CYP2A6, CYP2A13, and CYP2E1, none
of them offer a direct comparison because they all contain different ligands [5–9], and a
single cytochrome P450 enzyme can often bind different ligands with different active site
topologies. This appears to be especially true for CYP2E1, which is known to have
dramatically different active site volume and topography depending on the ligand [5, 6]. To
probe the differences and similarities between the human CYP2A and CYP2E1 enzymes, we
utilized the muscarinic receptor agonist pilocarpine ((3S,4R)-3-ethyl-4-((1-methyl-1H-
imidazol-5-yl)methyl)dihydrofuran-2(3H)-one, Figure 1). Pilocarpine was previously
identified as a competitive inhibitor of human CYP2A6, and to a lesser extent CYP2B6 [10,
11]. We have determined herein that pilocarpine also inhibits CYP2A13 and CYP2E1.
In the present study functional analysis of CYP2A13, CYP2A6, and CYP2E1 with
pilocarpine combined with X-ray structures of these complexes have allowed direct
comparisons among these three different human cytochromes P450. In addition, wild type
CYP2A13 and CYP2A6 were compared to a previously identified CYP2A6 mutant,
CYP2A6 I208S/I300F/G301A/S369G, that gained the ability to metabolize phenacetin like
CYP2A13 [12]. Previous studies suggested that these four residues were the primary
determinants for CYP2A phenacetin metabolism and might be important for differential
recognition of other ligands by CYP2A enzymes. The functional and structural results
presented herein allow for a direct comparison of all three enzymes and provides insight to
observed differences in inhibition by pilocarpine.
Results
Pilocarpine binding
Titrations of pilocarpine with CYP2A6, CYP2A6 I208S/I300F/G301A/S369G, and
CYP2A13 result in increases in absorbance at 424 nm and decreases at 420 nm, consistent
with a type II interaction in which a nitrogen coordinates to the heme iron (Figure 1A–C).
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Titrations of CYP2E1 with pilocarpine were more unusual (Figure 1D). At low pilocarpine
concentrations, absorption increases were observed at 391 nm and decreases at 430 nm,
indicative of a type I interaction in which pilocarpine binding displaces of a water molecule
from the heme iron but does not interact directly with the heme itself. However at higher
pilocarpine concentrations, the type I shift disappeared and a type II shift was observed
similar to the CYP2A enzymes. The dissociation constants for type II binding to all three
CYP2A enzymes were very similar (1.5–3.6 μM, Figure 1A–C), while the same parameter
for CYP2E1 was 10-fold higher (26.5 μM, Figure 1D).
Pilocarpine Inhibition
Pilocarpine inhibition constants were determined for CYP2A6, CYP2A6 I208S/I300F/
G301A/S369G, CYP2A13, and CYP2E1 using both common and selective substrates (Table
1). Coumarin was used as the selective substrate for all of the CYP2A enzymes, while
chlorzoxazone was used as an additional substrate for CYP2E1. Since CYP2E1, CYP2A13,
and CYP2A6 all metabolize p-nitrophenol, pilocarpine inhibition was also evaluated for all
three wild type enzymes with p-nitrophenol as the substrate. These results revealed that
pilocarpine is a competitive inhibitor of CYP2A13 for both coumarin and p-nitrophenol,
though the Ki is 34-fold higher for coumarin. CYP2A6 inhibition by pilocarpine revealed
mixed inhibition, with Ki values for both substrates 2-fold higher than for CYP2A13. The
CYP2A6 quadruple mutant I208S/I300F/G301A/S269G demonstrated competitive
inhibition with a Ki for inhibition of coumarin 7′-hydroxylation nearly identical to that of
wild type CYP2A13 with the same substrate. Pilocarpine inhibited CYP2E1 least effectively
with non-competitive inhibition with both chlorzoxazone and p-nitrophenol as substrates. By
comparison, pilocarpine had a Ki value for CYP2E1 546-fold greater than CYP2A13 with
the same substrate.
Structure of CYP2A6 with pilocarpine
The protein backbone of CYP2A6 with pilocarpine is very similar to other structures of
CYP2A6. The average root mean square deviations of the CYP2A6/pilocarpine structure
with available structures of CYP2A6 with coumarin, methoxsalen, N,N-dimethyl(5-
(pyridin-3- yl)furan-2-yl)methanamine, N-methyl(5-(pyridin-3-yl)furan-2-yl) methanamine,
(5-(pyridin-3-yl)furan-2-yl)methanamine and adrithiol is 0.24 Å [8, 9]. In the present
CYP2A6 structure, density for pilocarpine was located directly above the heme in all four
CYP2A6 molecules. This density clearly oriented pilocarpine with the imidazole ring closest
to the heme, with a distance of only 2.3 Å from the unsubstituted nitrogen in the imidazole
ring to the heme iron (Figure 2A). This is consistent with the type II spectral shift observed
in the spectral ligand-binding assay (Figure 1A). The furan ring packs against the I helix
with a weak hydrogen bond from the exocyclic keto oxygen of pilocarpine to the N297 NH2
donor (3.4 Å). The ethyl group of the furan ring is directed toward L370. Additional
residues that pack against pilocarpine include F107, F209, V117, F118, I300, L370, and
I366.
Structure of CYP2A13 with pilocarpine
The structure of CYP2A13 with pilocarpine has a protein backbone very similar to that of a
structure of CYP2A13 with indole [7] (RMSD 0.53 Å). Due to the lower (3.0 Å) resolution,
the density for pilocarpine was not as well defined in the CYP2A13 active site, but the
ligand could be modeled with reasonable certainty in six of the eight molecules. The 2|Fo|-|
Fc| map (Figure 2b, blue mesh) has one portion of the pilocarpine with poor coverage—the
ethyl side chain—but its placement was determined based on the σA-weighted composite
omit map (Figure 2B, pink mesh). Similar to the CYP2A6 structure, pilocarpine in the
CYP2A13 active site is oriented with the imidazole ring closest to the heme with a distance
of only 2.5 Å from the unsubstituted nitrogen to the heme iron. This is also consistent with
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the type II spectral shift observed in the spectral ligand binding assay for this enzyme
(Figure 1B). As in the case of CYP2A6, there appears to be a hydrogen bond from the furan
ring keto oxygen to N297 (3.0 Å). The furan ring is in a similar overall placement as in
CYP2A6 except for the ethyl side chain, which is directed in the opposite direction—toward
F300 rather than toward L370. Residues F107, A117, F118, F209, F300, L370, and L366 all
pack against pilocarpine in the CYP2A13 active site (Figure 2B).
Structure of CYP2A6 I208S/I300F/G301A/S369G with pilocarpine
The protein backbone of the CYP2A6 I208S/I300F/G301A/S369G mutant is very similar to
that of the same mutant with the substrate phenacetin bound (RMSD 0.27 Å). This CYP2A6
I208S/I300F/G301A/S369G structure also contained four copies of CYP2A6 in the
asymmetric unit and each copy contained density corresponding to pilocarpine clearly
defined above the heme. Like the CYP2A13 and the CYP2A6 structures, the imidazole ring
of pilocarpine is located close to the heme with the unsubstituted nitrogen 2.5 Å from the
heme iron (Figure 2C) consistent with the type II spectral shift observed in the spectral
ligand binding assay (Figure 1C). Although the plane of the furan ring is different in that it
stacks with F107 instead of against the I-helix as in CYP2A6 and CYP2A13, the hydrogen
bond from the keto oxygen on the furan ring to N297 (3.0 Å) is maintained. Additional
residues that pack against the pilocarpine include F107, V117, F209, F300, A301, I366, and
L370.
Structure of CYP2E1 with pilocarpine
The protein backbone of the CYP2E1 structure with pilocarpine is very similar to that of
CYP2E1 with indazole, 4-methylprazole, and omega-imidazolyl fatty acid analogs [5, 6]
with an average RMSD of 0.31 Å. Like the CYP2A structures, the density in this 2.35 Å
structure supported the clear placement of pilocarpine with the imidazole ring ~2.18 Å from
the heme iron (Figure 2D), consistent with the type II spectral shift observed at high
pilocarpine concentrations (Figure 1D). In this orientation no hydrogen bond is observed
between pilocarpine and active site residues. Despite the presence of D295 in CYP2E1 at the
position corresponding to N297 in CYP2A enzymes, in CYP2E1 D295 is shielded from
pilocarpine by I115 and, as a result, the CYP2E1 active site is much more hydrophobic.
Instead, pilocarpine is surrounded by several hydrophobic residues including I115, L368,
V364, and phenylalanines (F116, F106, F207, F298, and F478) with T303 as the only polar
residue.
Discussion
Comparison of CYP2A6 and CYP2A13
There are many similarities between the functional and structural characteristics of CYP2A6
and CYP2A13. CYP2A6 and CYP2A13 bind pilocarpine with similar, single-digit
micromolar affinities, and have only a two-fold difference in the Ki value with two different
substrates. The overall structural similarity is very high (RMSD 0.63 Å). The structural and
functional evidence agree that pilocarpine binds with an imidazole nitrogen directly
coordinated to the heme iron (Figure 1A, B and Figure 3A). Additionally, both structures
show the exocyclic oxygen of pilocarpine positioned within hydrogen bonding distance to
the conserved N297, one of only two polar residues lining the active site. The primary
difference in pilocarpine binding to these two wild type enzymes is in the orientation of the
ethyl group of the furan ring (Figure 3A). In CYP2A13, this ethyl group is directed toward
residue 300 and away from F118 and L370, while in CYP2A6 the ethyl group is oriented in
the opposite direction, towards F118 and L370 and away from residue 300. Residue 300 is a
phenylalanine in CYP2A13 and an isoleucine in CYP2A6, while F118 and L370 are
conserved. Although there are eleven first and second shell amino acid differences between
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the CYP2A6 and CYP2A13 active sites, the side chain present at position 300 may be one of
the most significant differences between the two active sites. The identity of the residue at
position 300 not only correlates with the ethyl orientation in pilocarpine in the CYP2A6 and
CYP2A13 structures reported herein, but also with the ability to bind and monooxygenate
phenacetin [12]. This is also a key residue in the binding of other ligands including 2′-
methoxyacetophenone, phenethyl isothiocyanate, and coumarin [13]. In addition to the role
for the nonconserved residue at position 300, there are also several differences in the
orientation of the three conserved phenylalanine residues, F118, F107, and F209, which line
the active site. Overall, the sizes of the two active sites are similar, with the CYP2A6
volume (281.7 Å3) slightly smaller than of CYP2A13 (309.4 Å3), but the proportions are
different (Figure 3B). The CYP2A13 active site has more space available for ligands near
F300 and F209 due to a combination of the phenylalanine at residue 300 and positioning of
F209 away from the active site in the CYP2A13 structure, while the CYP2A6 active site has
more volume available to the ligand near F118 and above L370 (Figure 3B).
Comparison of CYP2A6, CYP2A6 I208S/I300F/G301A/S369G, and CYP2A13
The CYP2A6 I208S/I300F/G301A/S369G quadruple mutant has a binding affinity for
pilocarpine similar to that for both CYP2A wild type enzymes, but a Ki for pilocarpine that
is essentially identical to CYP2A13 and thus 2-fold lower than CYP2A6 (Figure 1, Table 1).
Based on both this information and the ability of this CYP2A6 quadruple mutant to bind and
deethylate phenacetin like wild type CYP2A13 (as opposed to CYP2A6, which does not
bind phenacetin [12]), we had proposed that the CYP2A6 I208S/I300F/G301A/S369G
mutant might orient pilocarpine as observed in wild type CYP2A13 rather than as observed
in CYP2A6.
Comparison of the three pilocarpine CYP2A structures (Figure 3C) revels that two key
features are shared in all three structures: 1) the placement of the imidazole ring and direct
coordination of the nitrogen to the heme iron, and 2) a conserved hydrogen bond from the
keto oxygen on the furan ring to N297. In the CYP2A6 quadruple mutant, the ethyl side
chain of pilocarpine is oriented towards residue 300 and away from residues F118 and L370,
similar to the CYP2A13 wild type structure. Additionally, several residues are found in
essentially identical positions as CYP2A13, including the mutated residues F300, A301,
S208, and G369. However, despite maintaining a hydrogen bond to N297, the pilocarpine
furan ring is oriented very differently in the CYP2A6 I208S/I300F/G301A/S369G structure
(Figure 3C) compared to either the CYP2A6 or CYP2A13 structures. Instead of packing
against the I helix, the furan ring rotates in CYP2A6 I208S/I300F/G301A/S369G so that the
furan face is more parallel with F107. The two nearby residues that differ significantly in
their positions between the CYP2A6 quadruple mutant and CYP2A13 are the conserved
residues L370 and F118. In the CYP2A6 I208S/I300F/G301A/S369G mutant, the L370 side
chain is deflected away from the central active site compared to its position in CYP2A13 or
CYP2A6, allowing sufficient volume for the furan ring of pilocarpine to rotate in a different
manner than observed in CYP2A13 or CYP2A6 (Figure 3C). Residue F118 is found in the
same position in CYP2A6 I208S/I300F/G301A/S369G as the wild type CYP2A6, a position
that also results in additional active site volume (Figure 3C). In addition, there is one amino
acid in this region that differs between CYP2A13 and CYP2A6—residue 117, which is a
valine in CYP2A6 and the CYP2A6 quadruple mutant, and an alanine in CYP2A13. This
residue, in addition to the position of conserved residue L370, may play a role in the
positioning of pilocarpine in the active site of CYP2A6 along with residues 208, 300, 301,
and 369. Thus, although the CYP2A6 I208S/I300F/G301A/S369G mutant has nearly
identical functional characteristics to CYP2A13 with both the substrate phenacetin and the
inhibitor pilocarpine, it is not a complete structural mimic of the CYP2A13 active site for all
ligands.
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Comparison of the inhibitor pilocarpine in CYP2E1 vs. CYP2A enzymes
Functional evaluation indicates that CYP2E1 has a type II affinity for pilocarpine that is ~8-
fold lower than the wild type CYP2A enzymes and has a 250- to 550-fold higher Ki (Figure
1, Table 1). Pilocarpine binding to CYP2E1 is unusual in that at low concentrations of
pilocarpine, type I binding is observed, converting to type II binding at higher pilocarpine
concentrations (Figure 1D). This suggests that pilocarpine may bind in more than one mode.
In addition, inhibition assays with pilocarpine indicate that pilocarpine is a non-competitive
inhibitor of CYP2E1. The non-competitive nature of the inhibitor suggested that pilocarpine
might bind in a second mode or second location. There is evidence for a second binding site
in the sigmoidal kinetics of several human xenobiotic cytochrome P450 enzymes and some
structural evidence as well. Most notable is a crystal structure of CYP3A4 with the
antifungal ketoconazole which identified two molecules of ketoconazole in the active site,
one located close to the heme and the second located above the first [14]. The structure of
CYP2C9 with warfarin also has evidence of a secondary binding site as warfarin is located
too far from the heme for metabolism to occur [15]. However, the CYP2E1 structure with
pilocarpine showed no evidence for pilocarpine binding anywhere other than immediately
adjacent to the heme in the active site of CYP2E1. This is likely due to the very high
concentration of pilocarpine (100 mM) present in the crystallization condition. The type I
shift was only present at low concentration of pilocarpine (<10 μM).
CYP2A and the CYP2E1 enzymes have active sites that are primarily hydrophobic with a
roof composed of phenylalanine residues. Several of the key hydrophobic residues in
CYP2E1 have equivalents in the CYP2A enzymes (Figure 4A). For example, CYP2E1 has a
leucine at residue 368 that is structurally equivalent to the leucine at 370 in CYP2A
enzymes. There are also several structurally equivalent phenylalanine residues that result in
a very differently shaped active site in CYP2E1 compared to the CYP2A enzymes (F207,
F298, and F478 in CYP2E1 for the CYP2A F209, F300, and F480) (Figure 4A). At the
position corresponding to the hydrogen bond donor N297, the CYP2E1 active site has D295,
but it does not hydrogen bond with pilocarpine because I115 and F298 block the residue
from actually forming part of the active site. Perhaps due in part to these differences, the
pilocarpine orientation in the CYP2E1 active site is much more perpendicular to the heme
than in the CYP2A enzymes where this axis is more parallel to the I helix (Figure 4A). The
hydrogen bond interaction with N297 in CYP2A enzymes in addition to the imidazole ring
interaction with the heme may account for the higher binding affinity and lower Ki values
for pilocarpine in the CYP2A enzymes.
In the first shell of residues composing the CYP2E1 active site the absence an amino acid
corresponding to CYP2A N297 that can participate in a ligand-stabilizing hydrogen bond
may also explain why pilocarpine binding to CYP2E1 can display both type I and type II
interactions. In addition to the orientation observed in the structure with imidazole
interacting with the heme (type II), pilocarpine may also bind in a non-coordinating
orientation (type I). Available active site space suggests that pilocarpine may also be able to
bind so that the dihydrofuran ring orients toward the heme, with the exocyclic oxygen
interacting with the only hydrophilic amino acid, T303.
Comparison of the CYP2E1 active site with structures containing other ligands
The volume of the CYP2E1 active site is ~190 Å3 with the low MW ligands indazole or 4-
methylpyrazole and 420–470 Å3 with fatty acid substrate analogs of various chain lengths
[5, 6] (Figure 4B). The active site volume of CYP2E1 with pilocarpine is 332.7 Å3, a
volume slightly larger than the active sites of CYP2A6 and CYP2A13 with pilocarpine (280
and 310 Å3, respectively), and intermediate between the other reported CYP2E1 structures.
However, the active site topology with pilocarpine is different yet again from the other two
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types of 2E1 structures reported previously. Differences in the CYP2E1 active site
dimensions with fatty acid vs. low MW ligands arose through rotation of the F298 side chain
without a shift in the backbone [6]. The CYP2E1/pilocarpine backbone also overlays with
both of the other types of CYP2E1 structures, but in this case rotation of the F478 side chain
opens up the opposite wall of the active site to accommodate pilocarpine (Figure 4B).
The current set of structural and functional data allows for a detailed comparison of binding
of the same ligand across human cytochrome P450 subfamilies 2A and 2E. In the current
series, pilocarpine binding is different for both the CYP2A6 and CYP2A13 enzymes, as well
as for CYP2E1, and those disparities can be correlated to detailed differences in the
respective active sites. Overall, the binding of pilocarpine into the active site of CYP2A
enzymes appears to be driven primarily by hydrogen bonding with the conserved N297 and
steric interactions largely driven by both a small set of nonconserved residues (300, 301,
208, 369 and perhaps 117) and indirect effects of a few conserved residues such as L370 and
F209. In other words, the pilocarpine ligand largely adapts its conformation to fit into the
CYP2A active sites. Remarkably, the CYP2E1 active site appears to bind ligands in an
entirely different manner. The binding of pilocarpine induces yet a third distinct
conformation of the CYP2E1 active site, generated by changes in side chain conformations.
In other words, CYP2E1 demonstrates much larger variation in the active site topology to
accommodate various ligands. To date, none of the liganded structures of CYP2A enzymes
indicate this same type of flexibility. It remains to be seen if structures of CYP2A enzymes
with other ligands will reveal active sites that have essentially the same topology as those
already known, or if additional data points will reveal more diversity in the CYP2A active
site dimensions. This is especially true for CYP2A13 since only two structures have been
reported to date, including the one presented herein. If the CYP2A structures are much less
flexible than those observed for CYP2E1 and other xenobiotic cytochrome P450 enzymes,
this has positive implications for the accuracy of docking to predict drug metabolism and
procarcinogen bioactivation by these human CYP2A enzymes.
Experimental Procedures
Protein Design, Expression, and Purification
Truncated, His-tagged but fully functional versions of human CYP2A6, CYP2A6 I208S/
G301A/I300F/S369G, CYP2A13, and CYP2E1 proteins were designed, expressed, and
purified as described previously [5, 12].
Spectral Binding Assay
Ligand binding affinities were determined using a spectral ligand binding assay described
previously [13].
Enzyme Assay
All metabolism and inhibition assays used a reconstituted protein system (RPS) consisting
of 50 pmol of purified CYP2A or CYP2E1 protein incubated with 200 pmol NADPH-
cytochrome P450 reductase and 100 pmol cytochrome b5 in a 1:4:2 ratio for 20 minutes at
room temperature prior to use. This RPS mixture was added to assay buffer containing the
desired substrate and inhibitor. The samples were pre-incubated at 37° C for 3 minutes and
the reactions were initiated by the addition of 1 mM NADPH. Samples were incubated for
10 minutes at 37° C and the reaction was stopped with 300 μL of 20% trichloroacetic (TCA)
on ice. All standards and zero samples had 300 μL of 20% TCA added prior to the addition
of NADPH. Samples and standards were centrifuged at 4500 × g for 10 minutes.
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RPS was added to buffer (50 mM Tris, pH 7.4 and 5 mM MgCl2) containing coumarin and
pilocarpine. After completing the assay as described above, all samples and standards were
diluted by the addition of 1 mL (2A6) or 200 μL (2A13) of buffer (50 mM Tris, pH 7.4 and
5 mM MgCl2). The amount of 7-hydroxycoumarin present was determined by fluorescence
following HPLC separation. The 7-hydroxycoumarin metabolite was detected by
fluorescence with an excitation wavelength of 355 nm and emission wavelength of 460 nm.
The mobile phase consisted of 30% MeOH, 68% water, and 2% acetic acid with a 1 mL/min
flow rate and a sample volume of 10 μL.
para-Nitrophenol (PNP) 4-hydroxylation
RPS was added to 100 mM potassium phosphate pH 6.8 with 2 mM ascorbic acid (for
CYP2E1), p-nitrophenol, and pilocarpine. After assay completion as described above, the
amount of 4-nitrocatechol was determined following HPLC separation. A mobile phase of
27% acetonitrile and 0.2% acetic acid was run at a rate of 1 mL/min. Monitoring absorption
at 345 nm allowed the detection of 4-nitrocatechol at ~5 minutes with p-nitrophenol elution
at ~8 minutes.
Chlorzoxazone 6-hydroxylation
The RPS was added to 100 mM potassium phosphate buffer, pH 7.4 and varying
concentrations of chlorzoxazone and pilocarpine. Instead of trichloroacetic, sample reactions
were stopped after 10 minutes at 37° C by the addition of 25 μL of 60% perchloric acid.
Correspondingly standards and controls had 25 μL of 60% perchloric acid, instead of
trichloroacetic, added prior to the addition of NADPH. The 6-hydroxychlorzoxazone
metabolite was detected using an absorption wavelength of 287 nm on an HPLC with a
mobile phase consisting of 20% acetonitrile, 78% water, and 2% acetic acid with a 1 mL/
min flow rate.
Protein Crystallization, Data Collection, and Structure Determination
CYP2A6, CYP2A6 I208S/I300F/G301A/S369G, CYP2A13, and CYP2E1 were co-
crystallized with pilocarpine by hanging drop vapor diffusion. The CYP2A6/pilocarpine
crystals were grown from 500 μM CYP2A6 with 100 mM pilocarpine in CM elution buffer
(50 mM potassium phosphate buffer, pH 7.4, 20% glycerol, 1 mM EDTA, 0.5 M NaCl) with
2% Anapoe-35 in a 1:1 ratio with precipitant solution (30% PEG 3500, 0.175 M Tris, pH
8.5, and 0.2 M ammonium sulfate). The CYP2A6 quadruple mutant/pilocarpine crystal was
grown similarly using 100 μM CYP2A6 I208S/I300F/G301A/S369G protein with 100 mM
pilocarpine in CM elution buffer and 2% Anapoe-35 in a 1:1 ratio with a slightly modified
precipitant solution (30% PEG 3350, 0.100 M Tris, pH 8.5, and 0.200 M ammonium
sulfate). The CYP2A13/pilocarpine crystal was grown from a solution of 200 μM
CYP2A13, 100 mM pilocarpine, and 2% Anapoe-35 in CM elution buffer in a 2:1 ratio with
precipitant solution (30% PEG 3350, 0.175 M Tris, pH 8.5, and 0.2 M ammonium sulfate).
The CYP2E1 crystal was grown at 455 μM in a buffer containing 100 mM pilocarpine, 120
mM potassium phosphate, pH 7.4, 0.5 M sucrose, and 1 mM EDTA in a 1:1 ratio with
precipitant solution (8% PEG MME 2000, 12% isopropanol, and 0.1 M NaHEPES, pH 7.5).
Crystals were flash cooled in liquid nitrogen after being immersed in a cryoprotectant. For
all CYP2A crystals, the cryoprotectant consisted of 700 μL of synthetic mother liquor and
300 μL of 100% ethylene glycol. The cryoprotectant for CYP2E1 was 0.1 M NaHEPES, pH
7.5, 5% iso-propanol, and 1.4 M sucrose. X-ray diffraction data of CYP2A6, CYP2A6
I208S/I300F/G301A/S369G, and CYP2A13 each with pilocarpine were collected at the
Stanford Synchrotron Radiation Laboratory (Stanford, CA) on Beamline 9–2 using a 0.98 Å
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wavelength and temperature of 100 K. Data were processed using Mosflm and Scala [16,
17]. The CYP2E1/pilocarpine data set was collected on Beamline 17-BM at the Advanced
Photon Source and processed with HKL2000. All structures were solved by molecular
replacement with the program Phaser [17]. Model building and refinement of all structures
were done iteratively using COOT [18] and Refmac5 in the CCP4 suite [17]. Detailed
collection and refinement statistics are presented in Table 2.
The search model for CYP2A13 with pilocarpine was a 1.65 Å structure of CYP2A6 with
N-methyl(5-(pyridin-3-yl)furan-2-yl)methanamine (PDB 2FDV). A Matthew’s coefficient
of 2.88 with 57.4% solvent suggested 8 molecules in the asymmetric unit. Molecular
replacement identified 8 molecules in CYP2A13 with good packing. The 3.0 Å final model
of 2A13 with pilocarpine contains residues 32–494 in molecules A–H, heme, 6 pilocarpine
molecules, and 31 water molecules and is deposited in the PDB as 3T3S. The
crystallographic R-factor is 21.3% and the Rfree is 30.3%. In the Ramachandran plot, 86.2%
of the residues are in the most favored region, 13.0% in the additionally allowed, 0.5% in
the generously allowed, and 0.3% in the disallowed regions.
The search model for both CYP2A6 structures was a 1.9 Å structure of CYP2A6 complexed
with coumarin (PDB 1Z10, molecule B). The 2.4 Å structure of CYP2A6 with pilocarpine
contains residues 32–494 and heme in all four copies of the asymmetric unit, 4 pilocarpine
molecules, and 217 water molecules and is deposited in the PDB as 3T3R. The
crystallographic R-factor is 19.9% and the Rfree is 26.0%. In the Ramachandran plot, 91.5%
of the residues are in the most favored region, 8.2% in the additionally allowed, 0.4% in the
generously allowed, and 0.2% in the disallowed regions.
The 2.1 Å final model for 2A6 I208S/I300F/G301A/S369G with pilocarpine contains
residues 32–494 and heme in all four molecules, 4 pilocarpine molecules, and 504 water
molecules and is deposite in the PDB as 3T3Q. The crystallographic R-factor is 21.2% and
the Rfree is 25.7%. In the Ramachandran plot 91.2% of the residues are in the most favored
region, 8.1% in the additionally allowed, 0.3% in the generously allowed, and 0.2% in the
disallowed regions.
The 2.35 Å final model of CYP2E1 with pilocarpine contains residues 31–494, heme, and
pilocarpine in all four molecules. There were also 4 sucrose molecules and 772 water
molecules and is deposited in the PDB as 3T3Z. The crystallographic R-factor is 21.7% and
Rfree is 28.1%. In the Ramachandran plot 89.6% of the residues were in the most favored
region, 9.9% in additionally allowed, 0.2% in generously allowed, and 0.2% in the
disallowed regions.
In each structure the single residue found in the disallowed region of the Ramachandran plot
was well defined by electron density.
Protein Figures and Analysis
All protein figures were generated using PyMOL [19]. VOIDOO [20] was used to determine
active site volumes with a 1.4 Å probe size. All figures were made using molecule A for
CYP2A6, CYP2A6 I208S/I300F/G301A/S369G, and CYP2E1. All figures of CYP2A13
utilized molecule E as this molecule contained the best ligand density.
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Difference spectra upon titration of cytochrome P450 enzymes with pilocarpine and the
resulting binding constants. Black arrows indicate the direction of type II shifts. (A)
CYP2A6. (B) CYP2A13. (C) CYP2A6 I208S/I300F/G301A/S369G. (D) CYP2E1. Inset in
panel A is the structure of pilocarpine. In this last panel, the red arrows indicate the type I
spectral shifts that occur at lower concentrations of pilocarpine and black arrows indicate the
type II shifts observed at higher pilocarpine concentrations. Kd values are the average of
duplicate titrations, except for CYP2A13 where three titrations were performed.
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Pilocarpine binding in the active site of CYP2A enzymes. CYP2A6 in pink (A), CYP2A13
in yellow (B), and CYP2A6 I208S/I300F/G301A/S369G in green (C) and CYP2E1 in indigo
(D). In each panel the 2|Fo|-|Fc| electron density is 1.0 σ around the ligand and heme (blue
mesh). In 2B, the σA-weighted composite omit map is also shown in pink mesh.
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Structural comparisons of CYP2A enzymes. Heme is shown as black sticks and iron as a red
sphere. (A) Pilocarpine binds similarly in the CYP2A13 (yellow) and CYP2A6 (pink) active
sites with the imidazole nitrogen coordinated to the heme iron and the furan exocyclic
oxygen hydrogen bonded to N297. (B) CYP2A13 and CYP2A6 active sites (colored as
panel A) with corresponding mesh illustrating the cavity volumes. Increased active site
volume is available near residue 300 in CYP2A13 and near F118 in CYP2A6. (C)
Comparison of CYP2A13 and CYP2A6 active sites (colored as in panel A) with the
CYP2A6 I208S/I300F/G301A/S369G mutant (green). Although the imidazole ring/Fe
interaction and hydrogen bond to N297 are conserved, the furan ring of pilocarpine is
positioned differently in the CYP2A6 I208S/I300F/G301A/S369G mutant.
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Comparison of CYP2E1/pilocarpine complex to CYP2A structures with pilocarpine and to
CYP2E1 structures with other ligands. Heme is shown as black sticks with iron as a red
sphere. (A) The active sites of CYP2E1 (blue), CY2A6 (pink), and CYP2A13 (yellow) are
similar in that all three contain several hydrophobic residues, including key phenylalanines
which form the top of the active site (numbering is CYP2A/CYP2E1). (B) Comparison of
CYP2E1 showing the active site voids (as mesh) for three different ligands: pilocarpine
(blue), indazole (PDB 3E6I, cyan), and omega-imidazolyl-dodecanoic acid (PDB 3LC4,
magenta). Changes in the active site topology are largely due to reorientation of either the
F478 or F298 side chains with little alteration of the overall protein backbone. Figure is
presented as a wall-eyed stereo figure.
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Table 1
Inhibition constants for pilocarpine to CYP2A6, CYP2A6 I208S/I300F/G301A/S369G, CYP2A13, and
CYP2E1
Enzyme Substrate Type of Inhibition Ki (μM)a Ki/Ki2A13b
CYP2A13 Coumarin Competitive 48 ± 4 1
p-Nitrophenol Competitive 1.4 ± 0.1 1
CYP2A6 Coumarin Mixed, α=6.98c 101± 17 2.1
p-Nitrophenol Mixed, α=24.9 c 3.0 ± 0.5 2.1
CYP2A6 I208S/I300F/G301A/S369G Coumarin Competitive 49 ± 3 1
CYP2E1 Chlorzoxazone Non-competitive 360 ± 30
p-Nitrophenol Non-competitive 765 ± 30 546
a
All assays were preformed in triplicate.
b
Fold difference between indicated Ki and the Ki for CYP2A13 with the corresponding substrate.
c
Mixed inhibition with the larger alpha favors competitive inhibition, while the smaller alpha indicates more uncompetitive character to the
inhibition.
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Table 2
Crystal data collection and refinement statistics of cytochrome P450 enzymes binding pilocarpine.
2A6 2A6 I208S/I300F/G301A/S369G 2A13 2E1
Crystal Data
 Space group P21 P21 P1 P4
 Unit cell
  a, b, c (Å) 70.34, 158.00, 104.45 70.95, 159.8, 103.9 71.50, 119.86, 154.87 100.6, 100.6, 259.5
  α, β, γ(°) 90.0, 92.1, 90.0 90.0, 91.8, 90.0 101.0, 101.7, 93.6 90.0, 90.0, 90.0
 Molecules per AU 4 4 8 4
Data Collection
 Resolution (Å) 87.04–2.40 (2.46-2.40) 87.04-2.10 (2.16-2.10) 117.00 - 3.00
(3.16-3.00)
37.0-2.35 (2.41-2.35)
 Total observationsa 237,442 (17,456) 301,406 (21,586) 383,997 (55,808) 385,690 (18,326)
 Unique observationsa 85,624 (6,420) 126,622 (9,537) 96,716 (14,053) 102,444 (10,635)
 Completenessa (%) 96.5 (97.9) 94.3 (96.0) 98.3 (97.9) 95.9 (84.3)
 Multiplicitya 2.8 (2.7) 2.4 (2.3) 4.0 (4.0) 3.76 (2.04)
 Rmergea (%) 0.075 (0.400) 0.075 (0.400) 0.117 (0.634) 0.105 (0.221)
 I/σIa 13.2 (3.4) 9.3 (1.4) 9.4 (2.1) 6.6 (2.6)
Refinement Statistics
 Resolution (Å) 79.00 – 2.40 63.32 – 2.10 102.88 – 3.00 36.98-2.35
 No. reflections 81,313 120,218 91,882 97,337
 R/Rfree (%) 19.9/26.0 21.1/25.7 21.3/30.3 21.7/28.1
 Rms bond lengths (Å) 0.020 0.009 0.017 0.020
 Rms bond angles (°) 1.847 1.182 1.786 1.629
Number of atoms/Average B factor
  Protein 15,040/31.8 15,101/31.5 30,058/55.4 15,166/35.4
  Ligand 60/34.0 60/39.1 90/72.8 60/26.7
  Heme 172/20.2 172/21.3 344/52.2 172/22.1
  Sucrose 0 0 0 92/28.8
  Water 217/25.9 504/31.8 31/34.5 772/29.6
 Coordinate error, Luzzati
plot (Å)
0.277 0.254 0.388 0.321
a
Parenthesis indicate highest resolution shell.
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